All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-05-07T11:15:57.000Z

Pembrolizumab for R/R T-cell lymphoma: Results from a phase II trial

May 7, 2019
Share:

Bookmark this article

On 2 April 2019, Stefan Barta from the Fox Chase Cancer Center & the University of Pennsylvania, Pennsylvania, PA, USA, and colleagues, published in Clinical Lymphoma, Myeloma & Leukemia results from the first prospective phase II trial (NCT02535247) that investigated the efficacy of pembrolizumab for the treatment of relapsed of refractory (R/R) mature T-cell lymphoma.

Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor. Since PD-1 along with its ligand PD-L1 are commonly expressed in T-cell lymphomas and considering the current unmet need for patients with R/R T-cell lymphomas, the investigators sought to examine whether pembrolizumab is safe and can provide durable responses in this setting. The primary endpoint of this multicenter, prospective, single-arm, phase II trial was progression-free survival (PFS). Secondary outcomes included overall survival (OS), overall response rate (ORR), duration of response (DoR), and safety.

Study design & baseline characteristics

  • N = 18 patients with R/R mature T-cell lymphoma who had received ≥ 1 prior systemic therapy, with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, aged ≥ 18 years
  • Most common patient histologies (N = 17; one patient had ineligible histology):
    • Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS): n = 7 patients
    • Follicular T-cell lymphoma (FTL): n = 4 patients
    • Transformed mycosis fungoides: n = 3 patients
    • Other: n = 3 patients
  • Dosing:
    • Pembrolizumab: 200 mg intravenously, every 3 weeks for up to two years until disease progression (PD) or unacceptable toxicity
  • Median patient age (range): 71 (18−88) years
  • Male patients: 47% (n = 8)
  • Median number of prior lines (range): 2 (1−9)
    • Patients who had received > 2 prior lines: 35% (n = 6)
  • Patients refractory to last treatment: 65% (n = 11)
  • Two-stage study design with early stopping for futility if median PFS was ≤ 3 months (null hypothesis) versus ≥ 6 months

Key findings

  • Fifteen out of 17 patients provided response data, since one patient developed pneumonitis after one treatment cycle and the other one died of an unrelated toxicity
  • The trial was discontinued early for futility since six out of 11 patients evaluable for PFS at three months were progression free

Patients (response data)

N = 15

 

ORR (n)

33% (n = 5)

95% CI, 9−57

Complete response (CR; n)

27% (n = 4)

95% CI, 4−49

Median time to best response (range)

114 (81−146) days

 

Median follow-up

5.9 months

95% CI, 0−18

Median PFS

3.2 months

95% CI, 1.2−3.7

Median OS

10.6 months

95% CI, 3.2−100

  • Patients discontinuing study: 88%
    • Reasons for discontinuation:
      • PD: n = 11 patients
      • Death: n = 1 patient
      • Toxicities: n = 2 patients
    • Amongst the responders:
      • None experienced PD on treatment
      • One patient discontinued treatment due to vasculitis
      • One patient came off in CR to receive a hematopoietic stem cell transplant
      • Two patients remain in remission after > 15 months, still receiving treatment (median DoR, 2.9 months; 95% CI, 0−1)

Safety

  • The most common adverse events (AEs) were:
    • Rash: 17% (n = 3)
    • Hypothyroidism: 11% (n = 2)
    • Watering eyes: 11% (n = 2)
    • Chills: 11% (n = 2)
    • Edema: 11% (n = 2)
    • Fatigue: 11% (n = 2)
    • Fever: 11% (n = 2)
    • Injection reactions: 11% (n = 2)
    • Dyspnea: 11% (n = 2)
    • Pneumonitis: 11% (n = 2)
  • Number of patients who experienced Grade ≥ 3 AEs: 67% (n = 12)
    • Of those, 22% (n = 4) were considered treatment-related
  • Most common treatment-related Grade ≥ 3 AEs:
    • Pneumonitis (11%; n = 2)
    • Rash (11%; n =2)
  • No treatment-related deaths occurred. But one patient died while on treatment (septic shock)
  • Immune-related AEs occurred in n = 12 patients

Conclusions

According to the authors, the ORR observed in this trial (33%), with single-agent pembrolizumab in patients with R/R T-cell lymphoma, is comparable to other available monotherapy agents. In general, the PD-1 inhibitor showed modest activity and the expected toxicity profile. The main limitation of this study was its small sample size. Larger prospective studies are needed to validate the results of this trial.

  1. Barta S.K. et al. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Apr 3. pii: S2152-2650(18)31750-6. DOI: 10.1016/j.clml.2019.03.022 [Epub ahead of print].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox